Seeking Alpha7/31/2026Neutral
Innate Pharma: Pipeline Optionality Favors Speculative Bulls At These Levels
Innate Pharma has an interesting lineup of catalysts with the upcoming IPH4502 data, PACIFIC-9 results, and a potential financing solution for TELLOMAK-3. IPH4502's early responses across several solid tumors also give it some diversification beyond Monalizumab. PACIFIC-9 is IPHA's largest near-term catalyst, but AstraZeneca controls it, and IPHA is only eligible for milestone payments and royalties if it succeeds.